Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22344974 | 0.96 | ATM (0.32) | LMNA | |
| SCHEMBL22357075 | 0.95 | MEN1 (0.33) | HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL8663263 | 0.89 | SMN1; SMN2 (0.37) | HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL20528917 | 0.87 | HPGD (0.37) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL2734922 | 0.85 | SMN1; SMN2 (0.39) | HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL20528870 | 0.84 | HPGD (0.33) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL181009 | 0.84 | SMN1; SMN2 (0.41) | HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL1255461 | 0.84 | SMN1; SMN2 (0.41) | HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL22357158 | 0.82 | HPGD (0.36) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL180975 | 0.82 | SMN1; SMN2 (0.45) | HPGDHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11471537-B2 | Oligomer extended insulin-Fc conjugates | NOVO NORDISK A/S (DK) | 2022-10-18 | — | — | US | disclosed |
| US-20200261595-A1 | Oligomer Extended Insulin-FC Conjugates | NOVO NORDISK A/S (DK) | 2020-08-20 | — | — | US | disclosed |
| US-20200261595-A1 | Oligomer Extended Insulin-FC Conjugates | NOVO NORDISK A/S (DK) | 2020-08-20 | — | — | US | disclosed |
| EP-3606560-A2 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES | Novo Nordisk A/S (DK) | 2020-02-12 | — | — | EP | disclosed |
| WO-2018185131-A2 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES | NOVO NORDISK A/S (DK) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261595-A1 | Oligomer Extended Insulin-FC Conjugates | IAPP, IDE, INSR | HPGD 4347/4885HTT 52/4885SMN1; SMN2 2567/4885 |
| US-11471537-B2 | Oligomer extended insulin-Fc conjugates | IAPP, IDE, INSR | HPGD 4347/4885HTT 52/4885SMN1; SMN2 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.